Jus-Pharma was created, developed and patented by Founder, Chairman & CEO Beatrice O’Brien, who has assembled a highly acclaimed international team with a combined expertise of more than 100 years in clinical trials research, health care, pharmaceutical engineering, biotechnology, legal practice, business management and technological innovation.
Jus-Pharma is the revolution in clinical trials management that will forever change the speed, effectiveness, safety and economics of the clinical trials process throughout the pharmaceutical, biotechnology and medical devices industries.
Jus-Pharma – integrates, streamlines and secures every element of clinical trial study and communication to make the clinical trials process safer and more efficient.
Expert Guidance – Providing highest level expert guidance and support at every turn, Jus-Pharma optimizes communication amongst all parties from researchers, clinicians and patients to the C-suite executive team reporting to the board of directors.
Data – With recent data indicating that the average cost to develop a prescription drug that gains market approval is $2.6 billion US dollars, Jus-Pharma ensures that a clinical trial budget is judiciously attended while study management and controls become safer and more effective, advancing speed to market of new therapies and medications that improve global health and create a pathway for greater profitability.
Results – Such results allow best-in-class pharmaceutical researchers to continuously deploy capital to investigate and deliver to market the curative innovations of the future.
Transparency – Unifying the needs of investigators managing multi-site clinical trials, researchers gathering documentation and tracking regulatory compliance, investors seeking insights into the most promising therapies of the future while protecting enterprise assets and trial participants reporting symptoms to receive immediate medical attention as needed, Jus-Pharma delivers transparency to a formerly complex, disjointed ecosystem.
From the initial application through the pre-clinical stage, to the clinical trial phases and FDA approval, Jus-Pharma optimizes ROI, preserves capital, protects investors and mitigates litigation and safety risks while advancing efficiency in communication. Jus-Pharma is also a network that tracks, audits, and stores all documents, data and communications associated with a clinical trial. It facilitates secure text/voice/video communication/digital and voice signatures utilizing blockchain features between executives, researchers and participants.
For Pharmaceutical Companies
Our team assists pharmaceutical companies in evaluating data and verifying documents, making resource decisions, coordinating study site communications, managing regulatory compliance and identifying opportunities.
We analyze potential gains and risks. We troubleshoot. We simplify the clinical trials process for study participants, refraining from industry jargon and avoiding red tape.
We help pharmaceutical companies connect prospective trial participants with the ideal studies that address their unique challenges.
Jus-Pharma provides actionable insights that empower researchers, executives and investors to maintain confidence in their capital and resource investment in a trial.
We also provide a transparent Open Forum for all parties to ask and answer questions related to a clinical trial, creating an environment of trust.
For Contract Research Organizations
Acontract research organization can attract more clients by empowering the Jus-Pharma platform to be its competitive edge. Imagine improving, accuracy, safety and speed to market for client sponsors that outsource the clinical investigation process. With such unprecedented efficiency, CROs ensure delivery of results that optimize their clients’ market performance and catapult profitability.
Jus-Pharma provides support for CROs that receive investigatory assignments from both large and small or niche pharmaceutical and biotech companies.
The large corporations are typically under pressure to reward shareholders while the smaller niche companies seek to be recognized for speeding to market groundbreaking interventions, becoming ripe targets for extremely profitable acquisition by a larger corporation.
With Jus-Pharma, CRO companies outperform their competition and ensure their own enterprise stability and solvency as well as that of their clients.
TheJus-Pharma platform and support for CRO companies is identical to that which we provide to sponsor pharmaceutical and biotech organizations or military branches operating clinical trial centers. CROs receive the same efficiencies, blockchain technology and security as well as the chat, text and video interfacing capabilities and the Open Forum for all parties to exchange information.
Our CRO clients receive every single element we deliver to elite multinational corporate sponsors as well as the military branches that operate clinical testing centers. In short, Jus-Pharma has leveled the playing field for clinical trial innovation.
A CRO implementing Jus-Pharma protects and propels its competitive edge and marketability.
A CRO purchasing Jus-Pharma invites client confidence that it is managing a clinical trial in the most efficacious and judicious manner available.
A CRO with Jus-Pharma ability engenders investor confidence and amplifies its growth and acquisition opportunities, potentially elevating its market valuation exponentially.
For Clinical Trial Participants
Clinical trials can be intimidating and confusing. There are many instructions and conditions. Understanding the protocol, adhering to the program and posing the right inquiries can be challenging. Jus-Pharma optimizes the process, making it easier than ever to communicate with researchers. It puts tools in your hands to keep you fully informed throughout a clinical trial.
Learn MoreJus-Pharma delivers a team of experts that assists clinical trial participants throughout the process. We interpret industry jargon and eliminate red tape to provide clarity. We troubleshoot challenges. We connect participants with the right studies – and provide an Open Forum for all parties to ask and answer questions related to the clinical trials process.
Nearly 1,500 drugs and other therapies go into development each year with 80,000 clinical trials conducted annually in the United States. Fewer than ten percent of these compounds, vaccines and devices advance to the marketplace, thus underscoring a budgetary crisis for the entire clinical trials process that affects profitability and consumer cost. Jus-Pharma stems potential clinical trial losses before they have a chance to occur and potentially wreak financial havoc on a pharmaceutical enterprise or other clinical trial sponsor.
Jus-Pharma provides a transparency that illuminates challenging issues for trial sponsors, facilitating clear insights that enable early course correction, protecting capital investment and generating shareholder confidence that only the most promising compounds and other potential therapies will advance through each stage of a trial, preserving billions of dollars in capital for the industry and permitting executives, researchers and boards of directors to funnel study dollars only to those investigatory treatments with the highest likelihood of obtaining market approval.
Jus-Pharma is the only groundbreaking technology created and serviced by an expert team with over 100 years of combined professional experience that streamlines the clinical trials management process, preserving capital, mitigating risk, protecting enterprise stability and optimizing ROI. It empowers investors to maintain high confidence and ensures the enterprise remains an attractive buy.
Our Jus-Pharma Team
With more than a century of combined experience in the pharmaceutical development, biotechnology, legal, corporate and high-tech sectors, our team has an unparalleled record of combining clinical expertise with international business acumen.
The Jus-Pharma Advisory Board, team and technical staff have united to provide an unrivaled multi-industry mosaic of clinical intelligence. These highly credentialed strategists ensure never-before-seen efficiencies, a new level of industry transparency and a faster-than-ever time to market for pharmaceutical products and related therapeutic agents.
From the High Courts of England and Australia to top Wall Street firms, Founder, Chair and CEO Beatrice O’Brien brings more than 25 years of legal industry experience to the table. CEO O’Brien understands the complex nexus of global business and law that only an international lens can provide. CEO O’Brien was the first Fiji Indian attorney working at Wall Street law firm Cadwalader Wickersham & Taft.
Born in Suva in the Fiji Islands, CEO O’Brien was educated in Australia and became an (attorney) solicitor and barrister in the New South Wales Supreme Court. A facile legal mind has allowed her to develop a diverse depth of practice in corporate restructuring, litigation, corporate real estate, banking and tax law having worked in the UK and the US on some of the largest reorganization and restructuring cases in corporate history.
Ever the innovator, CEO O’Brien founded and leads Attorney Placements International (API), a global legal search, recruitment and consulting firm that facilitates law firm mergers and acquisitions moving entire legal practice groups to new firms and placing partners and associates with high-profile international clients. As an ardent educator, she has created revolutionary programs such as the New York Bar Review Quality Program which assists international attorneys in qualifying their unique skills and experience to practice in the US market.
Now, Beatrice O’Brien, in founding and leading JusGlobal, is introducing technology innovations backed by an assembly of diverse professionals with the highest credentialing to offer unprecedented insight, guidance and security across the legal, pharmaceutical, health care and military clinical trials space. She is a graduate of Bond University and Harvard Law School.
CEO O’Brien speaks fluent Hindi.
ADVISORY BOARD MEMBER
Partner with McKinsey & Company’s based in Hong Kong. Oliver brings to JusGlobal over 20 years international experience in strategy development, business development and start-ups. He is a graduate of Harvard Business School.
Mr. Ramsbottom speaks fluent Mandarin.
Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.
Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.
Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).
Dr. Eyal Ron adds value for Jus Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.
With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.
He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.
Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.
Dr. Evan Siegel, Ph.D.
CHIEF REGULATORY OFFICER
Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.
Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.
Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.
He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.
Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development.
Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.
Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.
Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).